CRBP vs. BMEA, MRSN, PEPG, MREO, TRDA, LXRX, AMRN, RVNC, ESPR, and TBPH
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Biomea Fusion (BMEA), Mersana Therapeutics (MRSN), PepGen (PEPG), Mereo BioPharma Group (MREO), Entrada Therapeutics (TRDA), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.
Corbus Pharmaceuticals presently has a consensus target price of $53.00, suggesting a potential upside of 22.43%. Biomea Fusion has a consensus target price of $53.25, suggesting a potential upside of 362.24%. Given Biomea Fusion's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Corbus Pharmaceuticals.
Corbus Pharmaceuticals received 398 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 66.67% of users gave Corbus Pharmaceuticals an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Corbus Pharmaceuticals has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500.
In the previous week, Biomea Fusion had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 9 mentions for Biomea Fusion and 6 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.05 beat Biomea Fusion's score of 0.18 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.
Biomea Fusion's return on equity of -69.88% beat Corbus Pharmaceuticals' return on equity.
Corbus Pharmaceuticals has higher revenue and earnings than Biomea Fusion. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Biomea Fusion beats Corbus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
